At a glance
- Originator Pfizer
- Class Anti-inflammatories; Bronchodilators
- Mechanism of Action 15-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 05 Sep 2006 Discontinued - Preclinical for Chronic obstructive pulmonary disease in United Kingdom (unspecified route)
- 16 Sep 2002 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (unspecified route)